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Abstract
Objective—To determine which of 3 HIV testing and counseling (HTC) models in outpatient 
departments (OPDs) increases HIV testing and entry of newly identified HIV-infected patients 
into care.
Design—Randomized trial of HTC interventions.
Methods—Thirty-six OPDs in South Africa, Tanzania, and Uganda were randomly assigned to 3 
different HTC models: (A) health care providers referred eligible patients (aged 18–49, not tested 
in the past year, not known HIV positive) to on-site voluntary counseling and testing for HTC 
offered and provided by voluntary counseling and testing counselors after clinical consultation; 
(B) health care providers offered and provided HTC to eligible patients during clinical 
consultation; and (C) nurse or lay counselors offered and provided HTC to eligible patients before 
clinical consultation. Data were collected from October 2011 to September 2012. We describe 
testing eligibility and acceptance, HIV prevalence, and referral and entry into care. Chi-square 
analyses were conducted to examine differences by model.
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Results—Of 79,910 patients, 45% were age eligible and 16,099 (45%) age eligibles were tested. 
Ten percent tested HIV positive. Significant differences were found in percent tested by model. 
The proportion of age eligible patients tested by Project STATUS was highest for model C 
(54.1%, 95% confidence interval [CI]: 42.4 to 65.9), followed by model A (41.7%, 95% CI: 30.7 
to 52.8), and then model B (33.9%, 95% CI: 25.7 to 42.1). Of the 1596 newly identified HIV 
positive patients, 94% were referred to care (96.1% in model A, 94.7% in model B, and 94.9% in 
model C), and 58% entered on-site care (74.4% in model A, 54.8% in model B, and 55.6% in 
model C) with no significant differences in referrals or care entry by model.
Conclusions—Model C resulted in the highest proportion of all age-eligible patients receiving a 
test. Although 94% of STATUS patients with a positive test result were referred to care, only 58% 
entered care. We found no differences in patients entering care by HTC model. Routine HTC in 
OPDs is acceptable to patients and effective for identifying HIV-infected persons, but additional 
efforts are needed to increase entry to care.
Keywords
counseling/methods; HIV infections/diagnosis; sero-prevalence; South Africa; Tanzania; Uganda
INTRODUCTION
HIV testing and counseling (HTC) is an important entry point to HIV prevention, care, and 
treatment, and an integral component of efforts to achieve universal access to HIV services. 
Identifying HIV positive persons and linking them to care and treatment can improve health 
outcomes1–5 and decrease HIV transmission through viral load suppression.5,6
To improve access to HIV prevention, care, and treatment services in developing countries, 
the World Health Organization and the Joint United Nations Programme on HIV/AIDS 
published guidance in 2007 calling for the scale-up of HTC in health facilities worldwide.7,8 
For countries with generalized HIV epidemics, this guidance recommends that in addition to 
client-initiated HTC, health care providers should recommend HTC as part of routine care, 
regardless of whether the patient shows signs and symptoms of HIV infection, or their 
reason for attending the health facility.7 More than 42 countries have adopted policies on 
HIV testing in a variety of health care settings including inpatient and outpatient 
departments (OPDs), antenatal care (ANC) and tuberculosis (TB) clinics, and emergency 
and surgical departments.9
Routine HTC is being successfully implemented in inpatient wards and in TB, sexually 
transmitted infection, and ANC clinics in many countries. Among countries receiving 
financial and technical assistance through the President’s Emergency Plan for AIDS Relief, 
HIV testing in some ANC clinics has exceeded 50% of attendees, with some testing more 
than 80%.10,11 HIV testing in TB clinics has also increased, reaching over 50% of patients 
in several countries.12 A review of studies of HTC implementation in clinical settings 
reports even higher levels of testing under controlled study conditions.13 These successes 
indicate that in appropriately resourced contexts, implementation of routine HTC is 
achievable.
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Several studies have reported feasibility and uptake of HIV testing in OPDs, showing that 
testing in OPDs is achievable,14–16 but rates of testing are relatively low compared with 
other clinical venues.13 As a primary source of health care for many people in developing 
countries, OPDs provide a venue for accessing large numbers of people from the general 
population. Although we do not know how many people accessing OPDs know their HIV 
status, OPDs may offer the opportunity to efficiently diagnose many infected persons before 
they develop life-threatening illness. Assessing the outcomes of HIV testing in OPDs would 
provide valuable information about the importance and feasibility of HIV testing in this 
setting and could inform policy-makers about how and why various HTC models may or 
may not be effective. Furthermore, determining whether different models of HTC delivery 
in the OPD vary in the number of HIV infected persons identified and linked to care and 
treatment services would be valuable information for decision makers trying to stretch HTC 
resources while assuring the greatest public health impact.
We present the findings of Project STATUS, a randomized trial of HTC interventions in 
OPDs in primary health care centers and district-level hospitals in South Africa, Tanzania, 
and Uganda. The primary objective of this evaluation was to compare 3 models of HTC in 
OPDs to determine which model results in the highest percentage of eligible outpatients 
receiving an HIV test and the highest percentage of HIV infected persons newly identified in 
the OPD who enter HIV care and treatment services.
METHODS
Study Design
Thirty-six OPDs in South Africa, Tanzania, and Uganda participated in Project STATUS. 
Each country selected a convenience sample of 12 OPDs in primary health care centers or 
district-level hospitals for inclusion in the study. Facilities varied in the size of their patient 
population but were comparable in the services offered and met the following inclusion 
criteria: OPD located at a district-level hospital or health care center in which less than 5% 
of outpatients were receiving routine HTC; provider-to-patient ratio of 1 health care 
provider providing care to 25–35 patients per day; on-site voluntary counseling and testing 
(VCT) center or services; space to conduct private HTC sessions; provision of HIV care and 
treatment services at the health facility; and ability to determine CD4 T-lymphocyte counts 
on-site or by sending blood samples to an off-site laboratory. Block randomization was used 
to assign the 12 OPDs in each country to one of 3 HTC models, resulting in 4 OPDs per 
model in each country or 12 OPDs per model across all 3 countries. Institutional review 
boards at the Centers for Disease Control and Prevention and in each country approved the 
study protocol.
In addition, patient interviews were conducted at all participating OPDs, 2 randomly 
selected OPDs per model per country conducted a time motion study, and 1 conveniently 
selected OPD per model per country participated in provider focus group discussions after 
the data collection period. These data are not reported in this article.
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At each participating health facility, health care providers, HTC nurse or lay counselors, and 
other relevant persons in the OPD were trained to deliver the HTC model to which their 
facility was randomized. Providers were trained on data collection procedures and the use of 
data collection tools. After a 2-month pilot study, data collection for HTC and HIV care 
entry was conducted for a 3-month study period (between October 2011 and September 
2012). STATUS participants who entered HIV care were followed for 4 months after care 
entry to determine whether they returned to care.
HIV Testing and Counseling—All patients attending a STATUS OPD during the study 
period were registered in a study log, in which age and sex were documented, and a unique 
study identifier was assigned. All OPD patients were given a packet containing a patient 
enumeration form (PEF) and referral cards, all marked with the patient’s unique study 
identifier (PEF number). Study staff documented patients’ age and sex on the PEF and 
requested that patients carry the packet with them throughout their visit. Patients in all 
models were eligible for HTC as part of Project STATUS if they were
• attending the OPD for a consultation with a health care provider for any routine or 
acute medical condition (excluding emergency cases),
• age eligible (18–49 years),
• test eligible (no documentation in patient records of having an HIV test in the past 
year or of ever testing HIV positive),
• able to provide informed consent for HIV testing.
The age of 18 was selected as the lower limit for study eligibility because it is the age of 
majority in the 3 participating countries; thus, patients 18 and older could legally provide 
verbal consent for HIV testing. The upper limit of 49 was selected to target persons at risk 
for HIV infection. OPDs typically see a high percentage of older patients, particularly the 
elderly, who would likely be at lower risk for HIV infection.
STATUS participants who tested HIV positive in all models were given a Project STATUS 
Care and Treatment Referral Card and encouraged to access on-site HIV care. The 3 HTC 
models are described below.
Model A: Health care providers referred eligible patients to on-site VCT services after 
clinical consultation. For age eligible patients, test eligibility was determined by the health 
care provider during the consultation. Test eligibility and referral to VCT were documented 
on the PEF by the provider, who referred test-eligible patients to VCT at the end of the 
consultation. For patients who went to VCT after their consultation, the VCT counselor 
documented whether they offered the patient HTC, whether they tested the patient, and the 
result. Patients testing HIV positive were referred to onsite HIV care by the VCT counselor, 
who also recorded referral data on the PEF.
Model B: All OPD patients in the waiting area heard a group talk that included HIV 
information. Eligible patients were offered HTC during clinical consultation. Test eligibility 
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of age eligible patients was determined by the health care provider, who also recommended 
and provided HTC during the consultation. The provider referred HIV positive patients to 
on-site HIV care and documented all testing and referral data on the PEF.
Model C: Eligible patients were offered and provided HTC before clinical consultation. Age 
eligible patients were sent to a waiting area separate from non–age eligible patients, where 
the age eligible patients heard a group talk about HIV. These patients were encouraged to be 
tested for HIV by a nurse or lay counselor before their clinical consultation and assured they 
would not lose their place in the queue to see the provider. Patients who chose to see the 
counselor had test eligibility determined by the counselor and were offered and provided 
HTC by the counselor before their consultation. Persons who tested HIV positive were 
informed of their result by the counselor, who documented all eligibility and testing data on 
the PEF. The OPD provider reviewed patients’ PEFs during the clinical consultation and 
referred HIV positive patients to on-site HIV care after the consultation. The provider 
documented referral data on the PEF.
OPD patients who did not meet STATUS age or test eligibility criteria, but wanted to 
receive a test, were provided testing; testing and referral data for these patients were not 
documented on their PEFs.
Entry Into HIV Care—Each model included referring all patients who tested HIV positive 
to on-site HIV care. Entry into HIV care was defined as having the patient’s information 
documented in the facility’s HIV care and treatment register and/or patient’s medical record. 
Project STATUS Care and Treatment Referral Cards included a peel-off sticker printed with 
the patient’s PEF number, which was affixed in the HIV care and treatment register to 
identify STATUS patients. Study staff were not able to assess care entry at non-STATUS 
HIV care and treatment facilities.
Analyses
We describe a cascade including age eligibility, test eligibility, receipt of HIV test, HIV 
prevalence, and referral to and entry into HIV care, in which each step in the cascade is 
dependent on the previous step. Rao Scott modified χ2 tests were conducted to examine 
differences by model for HIV test eligibility, testing rates, referral, and care entry. Analyses 
were conducted using SAS version 9.3.2 (SAS Institute, Cary, NC). All analyses, both 
descriptive and inferential, accounted for the study design by including the clustering within 
facility and stratification by country in the estimation of variances and 95% confidence 
intervals. In addition, because random selection of patients was not possible and the number 
of patients attending each OPD varied, there were unequal sampling rates across OPDs; 
therefore, sampling weights were used. These weights were created using the population 
size of the OPD during the study, the number of participants eligible for each outcome, and 
the number sampled. Therefore, different weights were used for estimating each outcome.
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Test Eligibility and Outcomes Among All OPD Attendees
During the 3-month study period, a total of 79,910 patients were registered in the 36 study 
OPDs. Forty-five percent of registered patients were age eligible, with a mean age of 29 
years. Seventy-four percent of age eligible patients were women. Sixty-one percent (n = 
22,034) of age eligible patients were determined to be test eligible (62% of all age-eligible 
women and 73% of all age eligible men). Providers determined 9987 age eligible patients 
were ineligible for testing; 6320 had documentation of a nonreactive test in the past 12 
months; and 3605 had documentation of a previous reactive test (patients could have both 
documentation of a nonreactive test in the past 12 months and of a previous reactive test). Of 
the age eligible patients, 16,132 (45%) were tested with an overall prevalence of 10% 
(women 10.0% and men 9.5%). HIV prevalence for STATUS patients was higher in South 
Africa (22%) than in Tanzania and Uganda (6% each). Ninety-four percent of the 1596 
newly diagnosed HIV-positive patients from the OPD were referred to HIV care, and fifty-
eight percent (n = 932) of those referred had documentation of registering at the on-site care 
and treatment clinic. We identified an additional 23 STATUS patients with documentation 
of entering care but no documentation of being referred to care.
Cascade of Testing Uptake, Referral to Care, and Care Entry by Model
In model A, 6564 (67%) age eligible participants were determined by the OPD provider to 
be test eligible during the clinical consultation (Fig. 1A). Eighty-three percent (n = 5448) of 
the 6564 eligible patients were referred to VCT, and 84% of all eligible patients actually 
went to VCT. Of those who went to VCT, 99% were offered testing, and 93% of patients 
offered testing accepted. Of the 445 persons who tested HIV positive, 95% were referred to 
care, and 75% of those who were referred entered care.
In model B, 57% of the age eligible participants were determined by the OPD provider to be 
test eligible during the clinical consultation (Fig. 1B). Model B providers indicated that they 
offered testing to 99% of test-eligible patients, and 65% accepted. Of the 520 persons who 
tested HIV positive, 94% were referred to care, and 57% of those who were referred entered 
care.
In model C, 9004 (80%) age eligible patients went to the HTC counselor before their clinical 
consultation (Fig. 1C). Seventy-eight percent were determined by the counselor to be test 
eligible, 99% of test-eligible patients were offered testing, and 92% accepted. Of the 631 
persons who tested HIV positive, 94% were referred to care, and 57% of those who were 
referred entered care.
Differences in Testing Rates, Referrals, and Care Entry by Model
No significant differences were found among models in the percentage of total patients 
attending the OPD or the percentage of patients who were age eligible or test eligible (Table 
1). When we examined the percentage of patients who were tested in the OPD among those 
who were age eligible, we found a significant difference by model (Table 2). The proportion 
of all age eligible patients who were tested was highest for model C (54.1%), followed by 
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model A (41.7%), and then model B (33.9%). When we examined the percentage of patients 
tested among those determined to be test eligible, we also found a significant difference by 
model with higher testing rates in model A (93.0%) and model C (91.9%) than in model B 
(65.5%) (Table 1). There were no significant differences by model in the percentage of 
patients found to be HIV positive or in the percentage of patients referred to care (96.1% in 
model A, 94.7% in model B, and 94.9% in model C). The percentage of referred patients 
who entered care was highest for model A (74.4%) compared with model B (54.8%) and 
model C (55.6%); however, this finding was not statistically significant. An additional 
analysis was conducted including those patients who entered care without documentation of 
referral, which also found no significant difference in care entry by model (data not shown).
DISCUSSION
Implementing HTC as Standard of Care
Despite World Health Organization’s recommendation that HTC be offered as a standard 
part of medical care in countries with generalized HIV epidemics7 and an increase in the 
implementation of HIV testing in sub-Saharan Africa (SSA),11,17 nationwide routine HTC in 
OPDs is still not a common practice. The benefits of implementing a policy of routine opt-
out HIV testing in SSA, including the potential for earlier antiretroviral therapy initiation 
and ultimately increased survival of persons with HIV, must be considered alongside the 
possible drawbacks of this approach such as patients thinking they cannot refuse or the 
stigma associated with a positive test result.18–21 Project STATUS demonstrated that it is 
feasible to routinely offer HTC to OPD patients and have substantial testing uptake, identify 
many undiagnosed HIV-infected persons, and have a substantial proportion enter HIV care 
soon after diagnosis.
Testing Uptake
STATUS resulted in high testing uptake with more than 81% of all persons offered testing 
accepting a test (16,132/19,953). Other studies have shown that routine HIV testing in health 
care settings is acceptable to patients and an effective method for increasing HTC 
uptake.15,22–24 For example, a study conducted in Zambian primary care clinics reported 
that 75% of patients with no proof of their HIV status who were offered HTC accepted 
under a model C–type arrangement.15
Patients were lost at different points in the cascade of each model. In model A, 16% of 
patients were never referred to VCT by the OPD provider, and not all who were referred 
went. Of those who went to VCT, 93% were tested. In model B, almost all test-eligible 
patients were offered HTC, but 35% declined. In model C, similar to model A, 20% of 
patients chose not to go to the area of the OPD where HTC was being offered, thereby 
essentially “opting out.” Of those who went, 92% were tested.
Given that patients in model C who “opted out” by not going to testing did not have their 
test eligibility determined, we compared testing rates by model among all age eligible 
patients rather than just test-eligible patients. The percentage of age eligible patients 
receiving a test was highest in model C. There are several possible reasons for this finding. 
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Model C OPDs had a separate waiting area for HTC located near the main waiting area and 
close to where testing was provided, allowing patients to conveniently test before their OPD 
consultation without worrying about losing their place in the queue to see the provider. 
Model C had designated staff trained and tasked to provide HTC, making the process quick. 
Unlike model A, there was no additional waiting time to receive HTC in model C; the 
waiting time to see the nurse or lay counselor for testing occurred during, not in addition to, 
the waiting time to see the OPD health care provider. Age eligible patients in model C OPDs 
also received a health talk from the OPD staff reinforcing the importance of knowing their 
HIV status and informing them that HIV care was available on-site for anyone with a 
positive result. Although model C resulted in the highest testing uptake, it also required 
substantial changes to OPDs’ standard operating procedures. Countries and OPDs 
considering implementation of this model must consider how changes to patient flow can be 
operationalized and how the additional staff needed to provide HTC before the OPD 
consultation can be effectively integrated.
The various methods currently being used in SSA have both strengths and limitations. 
Before the recommendation that health care providers routinely offer testing to all patients,7 
the most common practice in OPDs was provider referral to a VCT site within the health 
facility, similar to STATUS’ model A. This model is successful at identifying persons with 
HIV, as patients who perceive themselves to be at risk may be more motivated to test. 
However, those who perceive themselves to be at low risk may choose not to access VCT or 
to accept a test. Others may choose not to access services at the VCT because of the 
additional time required. In addition, previous studies have shown that uptake of HTC in a 
model A–type arrangement is lower among those experiencing poverty,25 who fear or have 
experienced stigma and discrimination,25,26 and who have lower education levels.27 
STATUS’ model B was modeled after the diagnostic testing approach used in some OPDs, 
in which health care providers offer and provide HTC during the clinical consultation to 
patients suspected of having HIV. Although implementing this model routinely can result in 
a high proportion of patients offered and receiving testing, its success depends largely on the 
actions and attitudes of the provider. Rather than conducting routine HTC, the provider may 
use clinical judgment to determine who may be HIV infected or at risk, resulting in patients 
who are asymptomatic or whom the provider perceives as having no risk not receiving 
HTC.7 A study by Dalal et al16 involving provider-initiated testing and counseling (PITC) 
under a model B–type arrangement identified increased workload and concerns regarding 
confidentiality as concerns of providers delivering this model. It is possible that providers in 
Project STATUS OPDs assigned to model B did not actually offer all eligible patients HTC 
because of the increased workload, confidentiality concerns, or other reasons, but indicated 
on the PEF that HTC was offered and the patient declined. Other studies have reported 
success with testing strategies similar to STATUS’ model C. A study in a South African 
OPD assessed a routine voluntary HIV testing intervention compared with the standard-of-
care provider-referral to a VCT site located in the same hospital complex as the OPD. 
Offering pretest information and HIV testing while patients waited to see the provider, the 
routine HTC intervention resulted in a 10-fold increase in HIV tests completed and over 4 
times as many HIV positive persons identified.14 A Zambian study that introduced PITC 
delivered by lay counselors in 9 urban primary care facilities tested twice as many patients 
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than when conducting VCT alone.15 The high acceptance of routine PITC in these studies 
and in Project STATUS may be due in-part to making HTC a standard feature of attending a 
health facility.7,15
Identification of HIV-Infected Persons, Referral to and Entry Into Care
Systematically offering HTC to all patients who visit the health facility increases the 
identification of HIV-infected patients.14 In Project STATUS across all 3 countries, 10% of 
patients who tested were newly identified with HIV. HIV prevalence rates in the STATUS 
OPDs were similar to estimates reported for the same period in the areas where the STATUS 
OPDs were located in South Africa (22% versus 24.7% in KwaZulu-Natal Province)28 and 
Uganda (6% versus 8.2% in Mid-Western Region).29 In Tanzania, rates in the STATUS 
OPDs were higher (6% versus 3.2% and 2.4% in Arusha and Tanga regions, respectively).30 
Although HIV case finding rates are higher in other health care settings,15,23,31 providing 
HTC in OPDs seems to be an effective method for identifying HIV positive individuals who 
are unaware of their status.
A goal of PITC is to link newly identified HIV-infected patients to care.7 Although 94% of 
the 1596 newly HIV-diagnosed patients from Project STATUS were referred, only 58% of 
them entered care at the STATUS facility. Although not significant, the highest percentage 
entering care by model came from model A, in which VCT counselors referred patients to 
care.
Referral to and entry into care for patients with newly diagnosed HIV remains an issue.32 A 
recent review of the operational implementation of PITC in SSA found linkage of newly 
identified HIV-infected patients to care was generally poor.13 Given that HIV care is easier 
to access from OPDs than other testing venues, we would expect higher rates of linkage. 
STATUS patients may have accessed care at other facilities. Clearly, additional research is 
needed to understand linkage patterns and determine how to motivate patients or to offer 
them the support needed to access care.
Limitations
Our study had several limitations. Across all models, the performance of the model was 
dependent on participation by facility staff and fidelity to the assigned model, which varied 
by facility. Since documentation of previous HIV testing is generally limited, persons who 
had already been tested in the past 12 months may have been tested again as part of Project 
STATUS because previous testing was not documented. Estimates of care entry are likely 
conservative. As we followed a cascade of study activities, STATUS patients who were not 
documented as being referred to care were excluded from the care entry analysis. Patients 
who did not enter care the day diagnosed but returned at a later date may not have returned 
with their Care and Treatment Referral Card and therefore were not identified as STATUS 
patients in the care and treatment register. Data were not collected at non-STATUS 
facilities, so patients who entered care at a different facility were not documented.
Project STATUS demonstrated that routine HIV testing in OPDs is acceptable to patients 
and an effective method for identifying HIV-infected persons, but additional efforts are 
needed to increase entry to care. Model C, in which nurse or lay counselors offered and 
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provided HTC to eligible patients before their clinical consultation, had the highest 
percentage of all patients aged 18–49 years receiving a test. Model C was convenient; there 
was no additional waiting time to receive HTC, and HTC was provided by staff specifically 
trained and tasked to conduct HTC. This study demonstrates an important venue and model 
that could increase access to life-saving HIV-related services.
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